Pfizer Investment Narrative Recap<\/p>\n
To own Pfizer today, you need to believe it can replace fading COVID and patent cliff revenues with new earnings from obesity, oncology and rare diseases while supporting a large dividend and debt load. The key near term catalyst is its late stage oncology readouts, with the biggest risk still execution on replacing expiring blockbusters under pricing pressure. HYMPAVZI\u2019s expanded hemophilia label and the new berobenatide data help the narrative but do not materially change that core risk reward balance.<\/p>\n
Among recent updates, the Phase 2b results for berobenatide, Pfizer\u2019s potential first in class monthly GLP 1 for obesity, look most relevant. If the Phase 3 VESPER program confirms competitive weight loss with less frequent injections, that could meaningfully support the longer term shift of Pfizer\u2019s earnings base toward obesity and related comorbidities, complementing the HYMPAVZI expansion and its growing oncology franchise as investors watch for mid 2026 cancer and obesity catalysts.<\/p>\n
Yet even with these positives, investors should be aware that patent expirations and policy driven pricing pressure could still…<\/p>\n
Read the full narrative on Pfizer (it’s free!)<\/a><\/p>\n Pfizer’s narrative projects $54.9 billion revenue and $9.2 billion earnings by 2029. This requires a 4.6% yearly revenue decline and an earnings increase of about $1.7 billion from $7.5 billion today.<\/p>\n Uncover how Pfizer’s forecasts yield a $29.19 fair value<\/a>, a 12% upside to its current price.<\/p>\n Exploring Other Perspectives Some of the most optimistic analysts already expected revenues near US$59.6 billion and earnings of about US$11.3 billion by 2029, so fresh HYMPAVZI and berobenatide news could push those bullish views even further while more cautious investors weigh how much regulatory pricing risks might still cap the upside.<\/p>\n Explore 21 other fair value estimates on Pfizer<\/a> – why the stock might be worth over 2x more than the current price!<\/p>\n Reach Your Own Conclusion<\/p>\n Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.<\/p>\n Searching For A Fresh Perspective?<\/p>\n Early movers are already taking notice. See the stocks they’re targeting before they’ve flown the coop:<\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data New: Manage All Your Stock Portfolios in One Place<\/p>\n We’ve created the ultimate portfolio companion for stock investors, and it’s free.<\/p>\n \u2022 Connect an unlimited number of Portfolios and see your total in one currency Try a Demo Portfolio for Free<\/a><\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"In early June 2026, Pfizer reported new Phase 2b data for its monthly GLP-1 obesity candidate berobenatide and…\n","protected":false},"author":2,"featured_media":444544,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[103,61,60,371],"class_list":["post-495673","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-ie","tag-ireland","tag-medication"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/495673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=495673"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/495673\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/444544"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=495673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=495673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=495673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"PFE](\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/06\/quote-price.png\")
<\/a>PFE 1-Year Stock Price Chart <\/p>\n
\n and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
\n financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
\n Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
\n Simply Wall St has no position in any stocks mentioned.<\/p>\n
\u2022 Be alerted to new Warning Signs or Risks via email or mobile
\u2022 Track the Fair Value of your stocks<\/p>\n